Oncology

Latest News

Evolving Roles of Antibody-Drug Conjugates in the Treatment of NSCLC

Evolving Roles of Antibody-Drug Conjugates in the Treatment of NSCLC

By Alana Hippensteele, MA

September 7th 2025

Antibody-drug conjugates are rapidly reshaping the treatment landscape of non–small cell lung cancer (NSCLC), with advances in design, clinical efficacy, and regulatory approvals tempered by ongoing challenges in toxicity, resistance, and biomarker optimization.

Microscopic view of non small cell lung cancer cells. Image Credit: © Keopaserth - stock.adobe.com

From Amivantamab to Next-Generation Therapies: The Evolving Bispecific Antibody Landscape in NSCLC

By Alana Hippensteele, MA

September 6th 2025

Lung cancer. Image Credit: © Dr Microbe - stock.adobe.com

Comparing Global Standards in Lung Cancer: NCCN, ESMO, and CHEST Guidelines

By Alana Hippensteele, MA

September 6th 2025

Most of the patients who experienced superior outcomes with atezolizumab and chemotherapy had higher levels of NOTCH1 expression. | Image credit: Pixel-Shot - stock.adobe.com

NOTCH1 Levels Impact Immune Response in SCLC

By Jared Kaltwasser

September 2nd 2025

The findings can help guide ongoing and future clinical trials to help solve remaining challenges in LS-SCLC. | Image credit: Jennifer - stock.adobe

Neoadjuvant Immunotherapy Plus Chemotherapy Shows Promise in LS-SCLC

By Jared Kaltwasser

August 31st 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

September 7th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

September 7th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Bidens Celebrate Progress, Highlight Need for More at Biden Cancer Summit

September 22nd 2018

Bidens Celebrate Progress, Highlight Need for More at Biden Cancer Summit

Jaime Rosenberg

The flagship event of more than 450 Biden Cancer Community Summits convening throughout the day is focusing on sharing experiences, promoting new solutions, and bridging gaps in cancer care.

More Data Necessary to Determine Best Treatment Option in Basal Cell Carcinoma

September 21st 2018

More Data Necessary to Determine Best Treatment Option in Basal Cell Carcinoma

Samantha DiGrande

Although many different treatments exist for basal cell carcinoma (BCC), many methods have not been compared in head-to-head randomized trials. A review recently published in Annals of Internal Medicine looked to evaluate the comparative effectiveness and safety of treatments in adults with BCC.

This Week in Managed Care: September 21, 2018

September 21st 2018

This Week in Managed Care: September 21, 2018

This week, the top managed care news included the Senate overwhelmingly voting to ban pharmacist gag clauses; a study found the current vaccine pipeline for HIV, tuberculosis, and malaria may fall short; an expert noted a trend of healthcare cost data seeping into nonhealthcare companies’ earnings calls.

$Amgen's AMG 420 Finds Early Success in Patients With Relapsing/Refractory Multiple Myeloma$

September 20th 2018

Amgen's AMG 420 Finds Early Success in Patients With Relapsing/Refractory Multiple Myeloma

Amgen’s pipeline drug AMG 420, a bispecific T-cell engager (BiTE) for the treatment of patients with relapsing/refractory multiple myeloma (RRMM), has found positive preliminary results in a phase 1 trial.

Dr Denalee O'Malley Highlights Gaps in Cancer Treatment Communication

September 19th 2018

Dr Denalee O'Malley Highlights Gaps in Cancer Treatment Communication

Assessing a patient’s understanding of his or her own illness is important as cancer treatments become more and more complex, said Denalee O’Malley, PhD, LSW, instructor, Department of Family Medicine and Community Health, Rutgers Robert Wood Johnson Medical School.

A Multidisciplinary Approach to Managing Complexities in Cancer Care

September 19th 2018

A Multidisciplinary Approach to Managing Complexities in Cancer Care

As September marks National Ovarian Cancer Awareness Month, we sat down with ovarian cancer survivor Marion Roth and Vaagn Andikyan, MD, gynecologic oncologist, Western Connecticut Health Network, to discuss Marion's cancer journey and the importance of a multidisciplinary care team in treating complexities in cancer care.

Prostate Cancer in Older Men Costs Medicare $1.2 Billion Over 3-Year Period

September 19th 2018

Prostate Cancer in Older Men Costs Medicare $1.2 Billion Over 3-Year Period

Jaime Rosenberg

With general consensus that those 70 years and older should not be routinely screened for prostate cancer, researchers argue that their study results identify an area for cutting low-value services to reduce healthcare spending.

Keytruda Earns Priority Review as Monotherapy in NSCLC

September 17th 2018

Keytruda Earns Priority Review as Monotherapy in NSCLC

Samantha DiGrande

Last week, the FDA granted priority review to a new supplemental Biologics License Application for pembrolizumab (Keytruda) as a monotherapy for first-line treatment of locally advanced or metastatic nonsquamous or squamous non–small cell lung cancer (NSCLC) in patients whose tumors express PD-L1 without EGFR or ALK mutations.

September 17th 2018

Low-Dose Aspirin Won't Prolong Life in Healthy Older People, Study Announces

The study by the National Institute on Aging produced a few surprises and was stopped early when aspirin showed no benefit.

NCCN Working Group Policy Recommendations Address Changing Paradigms in Cancer Care

September 16th 2018

NCCN Working Group Policy Recommendations Address Changing Paradigms in Cancer Care

Jaime Rosenberg

A National Comprehensive Cancer Network (NCCN) working group dedicated to analyzing current challenges under existing policy and treatment paradigms presented their findings and recommendations at an NCCN Policy Summit in Washington, DC.

Delivering High-Quality Care Under Value-Based Payment Models: Where Are We Now?

September 15th 2018

Delivering High-Quality Care Under Value-Based Payment Models: Where Are We Now?

Jaime Rosenberg

As the term “value” has become a norm in healthcare, specifically in oncology, panelists at a National Comprehensive Cancer Network policy summit offered perspectives on where we are now in delivering high-quality cancer care under value-based payment models.

Podcast: This Week in Managed Care—Pushback on Proposed Payment Rules and Other Health News

September 15th 2018

Podcast: This Week in Managed Care—Pushback on Proposed Payment Rules and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

NCCN Report on CAR T-Cell Therapy, Recommendations for Future Use

September 14th 2018

NCCN Report on CAR T-Cell Therapy, Recommendations for Future Use

Samantha DiGrande

A recent report from the National Comprehensive Cancer Network (NCCN) investigated the current state of chimeric antigen receptor (CAR) T-cell therapy and future strategies to consider as the novel immunotherapy evolves and is used in the treatment of more patients.

This Week in Managed Care: September 14, 2018

September 14th 2018

This Week in Managed Care: September 14, 2018

This week, the top managed care news included medical groups asking CMS to halt or slow down its plans to cut physician reimbursement for evaluation and management services; the Senate weighs a package of bills to combat the opioid epidemic; new research shows the Affordable Care Act pushed the uninsured rate down to 10%.

Dr Don Dizon Highlights Services Insurance Should Cover for Women Who Had Breast Cancer

September 14th 2018

Dr Don Dizon Highlights Services Insurance Should Cover for Women Who Had Breast Cancer

There are medications, procedures, and techniques that insurers could do a better job covering that would improve quality for women after breast cancer, said Don S. Dizon, MD, FACP, FASCO, director of Women's Cancers at the Lifespan Cancer Institute, director of medical oncology at Rhode Island Hospital, and associate professor of medicine at The Warren Alpert Medical School of Brown University.

Preventing Transportation of Mutant Protein Can Inhibit Growth of Leukemic Cells

September 13th 2018

Preventing Transportation of Mutant Protein Can Inhibit Growth of Leukemic Cells

Laura Joszt, MA

Researchers at Baylor College of Medicine have found that preventing a mutated protein from leaving the nucleus and traveling to the cytoplasm of the cell can help inhibit the growth of leukemic cells in acute myeloid leukemia.

Cautious Optimism: OCM Participants Seem to Have Improved in Performance Period 2

September 13th 2018

Cautious Optimism: OCM Participants Seem to Have Improved in Performance Period 2

Laura Joszt, MA

An early review of the second performance period of the Oncology Care Model (OCM) seems to show improvements over the first period.

September 13th 2018

Study Discerns Rare Risks of Fatal Side Effects From Cancer Immunotherapy

Allison Inserro

Researchers determined the incidence and timing of rare, fatal side effects from immune checkpoint inhibitors, and said the number is still extremely low.

EU Approves Keytruda for First-Line Treatment of Metastatic Nonsquamous NSCLC

September 12th 2018

EU Approves Keytruda for First-Line Treatment of Metastatic Nonsquamous NSCLC

Samantha DiGrande

Pembrolizumab (Keytruda) earned European approval this week, in combination with platinum-based pemetrexed, for the first-line treatment of metastatic nonsquamous non-small cell lung cancer (NSCLC) in adults whose tumors lack EGFR or ALK mutations.

September 11th 2018

OneOncology Launches to Enable Better Cancer Care in Communities Across America

Three leading oncology practices unite with partners in technology and finance to announce the launch of OneOncology, a patient-centric, physician-driven, and technology-powered company with a mission to improve the lives of everyone living with cancer.

Prescription Drug Coverage Improved Survival for Patients With MM

September 9th 2018

Prescription Drug Coverage Improved Survival for Patients With MM

Laura Joszt, MA

Patients with multiple myeloma (MM) who are enrolled in a Medicare Part D plan or other creditable prescription drug coverage have better survival than patients without prescription drug coverage. According to a study in Journal of Clinical Oncology, this improved survival seemed to be a result of patients having access to all treatment options.

HIV/AIDS Research Has Positive Impacts Across Other Medical Fields

September 6th 2018

HIV/AIDS Research Has Positive Impacts Across Other Medical Fields

Jaime Rosenberg

In addition to the advances made in the HIV space, such as antiretroviral therapies and pre-exposure prophylaxis, the years of research has translated into advances outside the HIV field, including in oncology and other immune diseases.

Bringing Virtual Tumor Boards, Real-Time Data to the Point of Care

September 5th 2018

Bringing Virtual Tumor Boards, Real-Time Data to the Point of Care

As the oncology landscape continues to rapidly evolve, access to real-time data has become increaisngly important, and technology-based medical startups have made their way to the front of the lines with point-of-care tools that use technology to transform cancer care.

Amgen Seeks Expanded Indication for Once-Weekly Kyprolis for Multiple Myeloma

September 4th 2018

Amgen Seeks Expanded Indication for Once-Weekly Kyprolis for Multiple Myeloma

Laura Joszt, MA

Amgen has submitted a supplemental New Drug Application to the FDA to expand the prescribing information of carfilzomib (Kyprolis) to include a once-weekly dosing option in combination with dexamethasone for patients with relapsed or refractory multiple myeloma.

Lay Health Workers May Provide Value for Patients With Cancer in New Payment Models

September 2nd 2018

Lay Health Workers May Provide Value for Patients With Cancer in New Payment Models

Laura Joszt, MA

As the healthcare system considers alternative payment models that reward high-value care delivery, programs that utilize lay health workers (LHW) may be valuable. A study in JAMA Oncology analyzed whether an LHW program can increase the documentation of patients’ care preferences.

What We're Reading: Calif. Drug Price Lawsuit Tossed; Testing ARBs for Cancer Link; Hope for Nonaddictive Painkiller

August 31st 2018

What We're Reading: Calif. Drug Price Lawsuit Tossed; Testing ARBs for Cancer Link; Hope for Nonaddictive Painkiller

A judge tossed a lawsuit brought by pharmaceutical companies to block a California law requiring advance notice of big price increases; the FDA is testing all angiotensin II receptor blockers (ARBs) over a discovered impurity that is linked to cancer; research in monkeys has suggested that an experimental painkiller is effective at easing pain without being addictive.

Dr Don Dizon: Discussing Sexual Health Needs With Patients With Cancer

August 31st 2018

Dr Don Dizon: Discussing Sexual Health Needs With Patients With Cancer

Most oncologists aren’t comfortable discussing sexual health needs with their patients, but there are places where sexual health services for patients with cancer are starting to gain foothold, said Don S. Dizon, MD, FACP, FASCO, director of Women's Cancers at the Lifespan Cancer Institute, director of medical oncology at Rhode Island Hospital, and associate professor of medicine at The Warren Alpert Medical School of Brown University.

Patients With Blood Cancer Less Likely to Understand Diagnosis Compared With Other Cancers

August 31st 2018

Patients With Blood Cancer Less Likely to Understand Diagnosis Compared With Other Cancers

Laura Joszt, MA

A survey of patients in the United Kingdom who were diagnosed with cancer found that patients with blood cancers were the least likely to say they completely understood what was wrong when the doctor explained it. They were also less likely to say that their treatment options were explained before treatment started compared with patients with other cancers.

August 30th 2018

Medicaid Expansion Helped Reduce Disparities Among Different Groups With Cancer

Allison Inserro

The expansion of Medicaid may mitigate health disparities in cancer diagnosis, according to a recent study that found state variation in reductions in the percentage of uninsured patients aged 18 to 64 years diagnosed with cancer. The researchers said that the results have implications for future disparities in state mortality rates, because health insurance coverage is linked to the ability to have better treatment and survival after diagnosis.

Childbirth Rates for Female Survivors of Hodgkin Lymphoma Similar to General Population

August 28th 2018

Childbirth Rates for Female Survivors of Hodgkin Lymphoma Similar to General Population

Laura Joszt, MA

As cure rates for young patients with Hodgkin lymphoma (HL) improve, the historically negative impact of treatments has to be considered. However, a new study has found that over time, childbearing rates for female survivors of HL have improved to the point of approaching the rates of the general population.

...

41 42 43 44 45 46 47 48 49

...

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions